ModifiedCapital BluecrossPolicy MP 2.190

Bioimpedance Devices for Detection and Management of Lymphedema

Governs coverage of bioelectrical impedance spectroscopy devices for detection and management of lymphedema in populations at risk (e.g., post-lymph node surgery or radiation), and states investigational use for other indications.

Policy Summary

PayerCapital Bluecross

PolicyBioimpedance Devices for Detection and Management of Lymphedema

Policy CodePolicy MP 2.190

Change TypeMaterial revision — MN expanded to at-risk individualsevidence and references updated

Effective DateJan 1, 2025

Next Review Date

Key ActionVerify member benefit and obtain preauthorization when required by the member's health benefit plan.

SourceLink

POLICY UPDATE CHANGES

Bioimpedance spectroscopy is now considered medically necessary for at-risk individuals.

References and updated guidelines (including PREVENT trial results) added to support coverage stance.

1Randomized trial (PREVENT) cited

3FDA-cleared devices listed

93702Procedure code (medically necessary)

BMI ≥30

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Bioimpedance Spectroscopy

Medically necessary use

Covered when ALL of the following are met

Covered indication: Device use is for individuals at risk of developing lymphedema (for example: undergoing breast cancer treatment; lymph node biopsy; regional lymphadenectomy; and/or radiation therapy for non-breast malignancies).

Supports measurement of extracellular fluid differences between limbs; FDA-cleared devices (eg, SOZO, MoistureMeterD, ImpediMed L-Dex) are indicated as aids to clinical assessment.

Investigational uses

Not covered / investigational

Investigational indications: Use of bioimpedance devices for all other uses not specified as for individuals at risk for lymphedema is considered investigational due to insufficient evidence.

May be denied when not related to lymph node removal, damage, or irradiation; insufficient evidence for general use.

Device limitations: Some FDA-cleared devices are labeled only to aid clinical assessment and are not intended alone to diagnose or predict lymphedema of an extremity.

See device-specific indications (eg, MoistureMeterD and ImpediMed L-Dex labeling).

Medically Necessary — At-Risk Individuals

Covered when criteria for at-risk individuals are met per policy update

BIS for at-risk individuals: Bioimpedance spectroscopy (BIS) is considered medically necessary for individuals at risk for lymphedema (policy updated to medically necessary for at-risk individuals).

Policy update (02/16/2024) reflects supporting evidence including the PREVENT randomized trial showing lower intervention trigger and lower progression rates with BIS versus tape measurement (eg, trigger rates 20.1% vs 27.5%; progression 7.9% vs 19.2% at median 32.9 months).

Some FDA-cleared bioimpedance spectroscopy devices carry labeling that limits their role to supporting the clinician's assessment rather than providing a standalone diagnosis or prediction of lymphedema. For example, device indications state they "support the measurement of extracellular fluid volume differences between the limbs" and are presented as an "aid to clinical assessment," and explicitly note the device is "not intended to make a diagnosis or predict lymphedema" for an extremity.

The existence of this medical policy does not guarantee that the services described are covered under a particular member's health benefit plan. Coverage decisions are determined by the member's specific benefit plan language, which may include exclusions, limits, or preauthorization requirements; providers should consult the applicable plan or contact Capital Blue Cross for benefit verification.

Use of bioimpedance spectroscopy devices for indications other than individuals at risk for developing lymphedema (as defined in this policy) is considered investigational and therefore not medically necessary due to insufficient evidence to support other uses.

In the provided excerpt there are no additional explicit conditions listed under a separate "not medically necessary" section beyond the investigational statement for non–at‑risk indications; coding notes emphasize that identifying a code in the policy does not by itself denote coverage.

Coding and Risk Factors

Regulatory/Product Codemixed

OBH	FDA product code for bioimpedance devices for lymphedema

Medically Necessary Procedure CodesCPTCovered

93702

Procedure Code listed under Medically Necessary Procedure Codes (as presented in policy)

BMI risk factor — BMI >= 30 kg/m2

BMI threshold>= 30 kg/m2

Risk contextHigher BMI increases risk of developing lymphedema after lymph node surgery or radiation

Associated factorsOther risk factors include localized infection, increased number of nodes removed, and higher initial extent of disease

Provider Actions and Requirements

Note

Product and Program Applicability

This policy and coverage may vary by Capital Blue Cross product or program. Confirm applicability to the member's specific plan before proceeding.

Applicable to certain Capital Blue Cross products and programs only; see product-specific benefit variations in Section VI (Benefit Variations).
FEP PPO: Refer to the FEP Medical Policy Manual (see policy notes).

Denial Risk

Benefit Determination and Coverage Risk

The presence of an FDA-cleared device or a billing code does not guarantee coverage. Benefit determinations must be made according to the member's health benefit plan.

Identification of a code in the coding section or FDA clearance does not imply coverage.
Coverage, exclusions, benefit limits, and preauthorization requirements are defined by the member's benefit plan language.

Background and Clinical Context

Lymphedema results from accumulation of interstitial fluid due to disruption or damage to lymphatic drainage. In adults this commonly occurs secondary to cancer treatments such as lymph node biopsy, regional lymphadenectomy, or radiation therapy; risk is increased in patients who have had lymph nodes removed, damaged, or irradiated. Early stages (latent or reversible swelling) are more amenable to intervention than later, fibrotic stages, so identification of at‑risk individuals after cancer treatment is a key focus of surveillance.

Definitions and Staging

Bioimpedance spectroscopy (BIS) — measurement explanation and relation to extracellular fluid

Measurement principleBIS measures tissue impedance; impedance decreases as interstitial/extracellular fluid increases

What it assessesUsed to assess extracellular fluid volume differences between limbs to support early detection of lymphedema

Clinical roleProposed as a diagnostic/monitoring adjunct to enable earlier intervention for subclinical lymphedema

Lymphedema stages — Stage 0-3 clinical staging described

Stage 0 (latent/subclinical)Lymphatic dysfunction without visible swelling; may have subtle symptoms (heaviness, fatigue); no overt edema

Stage 1 (reversible)Accumulation of fluid and protein causing swelling; pitting edema may be evident; swelling often relieved with elevation